A Phase 1/2 interventional study of SARS-CoV-2 mRNA vaccine formulation 1 and SARS-CoV-2 mRNA vaccine formulation 2 in COVID-19, sponsored by Sanofi Pasteur, a Sanofi Company. Terminated at 21 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-11.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 507th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 62 in phase 1/2, and was the 1,005th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 504 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 182 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
Sanofi has 6 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of the study are:
The secondary objectives of the study are:
The duration of each participant's participation in the study was approximately 365 days post-last injection: approximately 386 days duration for participants receiving 2 injections and approximately 365 days duration total for participants receiving a single injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR
A participant of childbearing potential must had a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours before the study intervention.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received two intramuscular (IM) injections of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Vaccine ultra-low dose on Day 1 and at Day 22, respectively.
Biological: SARS-CoV-2 mRNA vaccine formulation 1
Participants received two IM injections of SARS-CoV-2 Vaccine low dose on Day 1 and at Day 22, respectively.
Biological: SARS-CoV-2 mRNA vaccine formulation 2
Participants received two IM injections of SARS-CoV-2 Vaccine medium dose on Day 1 and at Day 22, respectively.
Biological: SARS-CoV-2 mRNA vaccine formulation 3
Participants received a single IM injection of SARS-CoV-2 Vaccine ultra-low dose on Day 1.
Biological: SARS-CoV-2 mRNA vaccine formulation 1
Participants received a single IM injection of SARS-CoV-2 Vaccine low dose on Day 1.
Biological: SARS-CoV-2 mRNA vaccine formulation 2
Participants received a single IM injection of placebo matched to SARS-CoV-2 Vaccine on Day 1.
Biological: Placebo (0.9% normal saline)
Participants received two IM injections of SARS-CoV-2 Vaccine ultra-low dose on Day 1 and at Day 22, respectively.
Biological: SARS-CoV-2 mRNA vaccine formulation 1
Participants received two IM injections of SARS-CoV-2 Vaccine low dose on Day 1 and at Day 22, respectively.
Biological: SARS-CoV-2 mRNA vaccine formulation 2
Participants received two IM injections of placebo matched to SARS-CoV-2 Vaccine on Day 1 and at Day 22, respectively.
Biological: Placebo (0.9% normal saline)
Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
Pharmaceutical form: Liquid Route of administration: Intramuscular injection
Number of Participants Reporting Immediate Unsolicited Adverse Events (AEs)
AE: any untoward medical occurrence in clinical investigation participant administered medicinal product \& which did not have any causal relationship with the treatment. Unsolicited AE: observed AE that did not fulfill conditions prelisted in case report form (CRF) in terms of diagnosis \&/or onset window post-vaccination. All participants were observed for 30 minutes after vaccination, \& any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in CRF. Reported AEs were presented as pre-specified in protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.
Time frame: Within 30 minutes post any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])
Number of Participants With Solicited Injection Site Reactions
Solicited reaction (SR): expected adverse reaction (sign or symptom) observed \& reported under conditions (nature \& onset) prelisted (i.e., solicited) in CRF and considered as related to product administered. Solicited injection site reactions included pain, erythema, \& swelling. Reported AEs for each arm were presented as pre-specified in study protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.
Time frame: Within 7 days after any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])
Number of Participants With Solicited Systemic Reactions
SR was an expected adverse reaction (sign or symptom) observed \& reported under conditions (nature \& onset) prelisted (i.e., solicited) in CRF \& considered as related to product administered. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia \& chills. Reported AEs for each arm were presented as pre-specified in study protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.
Time frame: Within 7 days after any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])
Number of Participants With Unsolicited Adverse Events
An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product and which did not have any casual relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset window post-vaccination. Reported AEs for each arm were presented as pre-specified in the study protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.
Time frame: Within 21 days after any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])
Number of Participants Reporting Serious Adverse Events (SAEs), Adverse Event of Special Interest (AESIs) and Medically Attended Adverse Events (MAAEs)
SAEs: any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs: event for which ongoing monitoring \& rapid communication by investigator to the sponsor was done. MAAE was a new onset or worsening of a condition that prompted participant or participant's parent/legally acceptable representative to seek unplanned medical advice at physician's office or emergency department. Reported AEs for each arm were presented as pre-specified in study protocol.
Time frame: From Day 1 until 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 groups and up to Day 387 for Cohort 2 groups)
Number of Participants With Laboratory Test Results Based on US Food and Drug Administration (FDA) Toxicity Grading Guidance
Laboratory tests: hemoglobin (male \& female), above \& below normal white blood cell, lymphocytes, neutrophils \& eosinophils, platelet count, creatinine \& blood urea nitrogen, hyponatremia \& hypernatremia, hyperkalemia \& hypokalemia, hyperglycemia (non-fasting), hypoproteinemia, alkaline phosphate, alanine aminotransferase, aspartate aminotransferase, bilirubin (with any increase in liver function test \[LFT\], bilirubin (normal LFT), prothrombin \& partial thromboplastin time (seconds), Urine: protein, glucose \& blood. US FDA "Toxicity Grading Scale for Healthy Adults \& Adolescent Volunteers" was used for grading; Grade 1=mild, Grade 2=moderate \& Grade 3=severe. In the data table, 'number analyzed'=participants with available data for each specified category \& '0'=none of participants were available for assessment for specified Group.
Time frame: From Day 1 up to up to 8 days post last vaccination (i.e., up to Day 9 for Cohort 1 groups; up to Day 30 for Cohort 2 groups)
Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 1
GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution. Data for this OM was planned to be collected and analyzed for combined population (FEC+ Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
Time frame: Day 1 (pre-vaccination)
Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 22
GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.
Time frame: Day 22 (post-vaccination)
Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 36
GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.
Time frame: Day 36 (post-vaccination)
Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22
SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 1.
Time frame: Day 1 (pre-vaccination) and Day 22 (post-vaccination)
Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36
SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (Day 36) and pre-vaccination (on Day 1) i.e., Day 36/Day 1.
Time frame: Day 1 (pre-vaccination) and Day 36 (post-vaccination)
Percentage of Participants With >=2-fold and >=4-fold Rise in Serum Neutralization Antibody Titers at Day 22
SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 1.
Time frame: Day 1 (pre-vaccination) and Day 22 (post-vaccination)
Percentage of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titer at Day 36
SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (on Day 36) and pre-vaccination (on Day 1) i.e., Day 36/Day 1.
Time frame: Day 1 (pre-vaccination) and Day 36 (post-vaccination)
Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22
Seroconversion was defined as participants with a Baseline (Day 1) titer values below lower limit of quantification (LLOQ) with a detectable neutralization antibody titer above assay LLOQ post injection (at Day 22). LLOQ of the neutralization assay was a titer of 10.
Time frame: Day 22 (post-vaccination)
Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36
Seroconversion was defined as participants with a Baseline (Day 1) titer values below LLOQ with a detectable neutralization antibody titer above assay LLOQ post injection (at Day 36). LLOQ of the neutralization assay was a titer of 10.
Time frame: Day 36 (post-vaccination)
Geometric Mean Concentration (GMC) of Anti-S Binding Antibody at Day 1, 22, 36, 91, 112, 181, and 202
GMC of Anti-S binding antibodies were assessed using enzyme-linked immunosorbent assay (ELISA) and were measured in ELISA unit/mL (ELU/mL). Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
Time frame: Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 91 (only for Cohort 1), Day 112 (only for Cohort 2), Day 181 (only for Cohort 1), and Day 202 (only for Cohort 2)
Geometric Mean Fold-rise (GMFR) of Binding Antibody Concentration at Day 22, 36, 91, 112, 181, and 202
Binding antibody titers were evaluated by ELISA. Fold-rise was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 22/Day 1, Day 36/Day 1, Day 91/Day 1, Day 112/Day 1, Day 181/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
Time frame: Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 91 (only for Cohort 1), Day 112 (only for Cohort 2), Day 181 (only for Cohort 1), and Day 202 (only for Cohort 2)
Percentage of Participants With >=2- and >=4- Fold Rise in Anti-S Binding Antibody Concentration at Day 22, 36, 91, 112, 181, and 202
Binding antibody titers were evaluated by ELISA. Fold-rise (2-fold and 4-fold) was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 22/Day 1, Day 36/Day 1, Day 91/Day 1, Day 112/Day 1, Day 181/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
Time frame: Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 91 (only for Cohort 1), Day 112 (only for Cohort 2), Day 181 (only for Cohort 1), and Day 202 (only for Cohort 2)
Geometric Mean Titers of Neutralizing Antibody Titer Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 91, 112, 181, and 202
GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
Time frame: Cohort 1: Day 91, Day 181 and Cohort 2: Day 112, and Day 202 (post-vaccination)
Geometric Mean Fold-rise of Serum Neutralization Antibody Titer at Day 91, 112, 181, and 202
SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., for Cohort 1: Day 91/Day 1, Day 181/Day 1; Cohort 2: Day 112/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
Time frame: Day 1 (pre-vaccination), Cohort 1: Day 91, Day 181 and Cohort 2: Day 112, and Day 202 (post-vaccination)
Percentage of Participants With 2-Fold and 4-Fold Rise in Serum Neutralization Antibody Titer at Day 91, 112, 181, and 202
SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise (2-fold and 4-fold) was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 91/Day 1, Day 112/Day 1, Day 181/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
Time frame: Day 1 (pre-vaccination), Cohort 1: Day 91, Day 181 and Cohort 2: Day 112, and Day 202 (post-vaccination)
Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens
Seroconversion was defined as participants with a Baseline (Day 1) titer values below lower limit of quantification (LLOQ) with a detectable neutralization antibody titer above assay LLOQ post injection. LLOQ of the neutralization assay was a titer of 10. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
Time frame: Cohort 1: Day 91, Day 181 and Cohort 2: Day 112, and Day 202 (post-vaccination)
Number of Participants With Virologically-confirmed Coronavirus Disease (COVID-19)-Like Illness
Virologically-confirmed COVID-19-like illness was defined by specified clinical symptoms and signs and confirmed by positive result for SARS-CoV-2 by nucleic acid amplification test (NAAT) on a respiratory sample in association with a COVID-19-like illness.
Time frame: Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)
Number of Participants With Serologically-confirmed SARS-CoV-2 Infection
Serologically-confirmed SARS-CoV-2 infection as defined by SARS-CoV-2 Nucleoprotein specific antibody detection immunoassay was reported in this outcome measure.
Time frame: Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)
Correlates of Risk/Protection Based on Antibody Responses to SARS-CoV-2
Correlate of risk / protection based on antibody responses to SARS-CoV-2 was evaluated using virus neutralization or ELISA, considering virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection.
Time frame: Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)
The study was conducted at 17 active sites in 4 countries between 12 Mar 2021 and 27 Jun 2022. Study consisted of 2 cohorts: Sentinel Cohort and Full Enrollment Cohort (FEC). For analysis purpose, Baseline, safety and outcome measure data was planned to be collected, analyzed and reported for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
| Milestone | Sentinel Cohort: SARS-CoV-2 Vaccine Ultra Low Dose | Sentinel Cohort: SARS-CoV-2 Vaccine Low Dose | Sentinel Cohort: SARS-CoV-2 Vaccine Medium Dose | FEC Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | FEC Cohort 1: SARS-CoV-2 Vaccine Low Dose | FEC Cohort 1: Placebo | FEC Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | FEC Cohort 2: SARS-CoV-2 Vaccine Low Dose | FEC Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 25 | 10 | 27 | 26 | 13 | 28 | 29 | 14 |
| Vaccinated on day 1 | 10 | 25 | 10 | 27 | 25 | 13 | 28 | 28 | 14 |
| Vaccinated on day 22 | 10 | 24 | 10 | 0 | 0 | 0 | 19 | 19 | 9 |
| Safety analysis set (safas) | 18 | 17 | 10 | 36 | 34 | 18 | 19 | 19 | 9 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 10 | 25 | 10 | 27 | 26 | 13 | 28 | 29 | 14 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 1 | 1 | 1 | 3 | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by sponsor | 8 | 22 | 9 | 26 | 24 | 11 | 25 | 26 | 11 |
AE: any untoward medical occurrence in clinical investigation participant administered medicinal product \& which did not have any causal relationship with the treatment. Unsolicited AE: observed AE that did not fulfill conditions prelisted in case report form (CRF) in terms of diagnosis \&/or onset window post-vaccination. All participants were observed for 30 minutes after vaccination, \& any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in CRF. Reported AEs were presented as pre-specified in protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.
| Participants | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Group 3: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Post Any vaccination | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Post vaccination 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Post vaccination 2 | — | — | — | 0 | 0 | 0 | 0 |
Solicited reaction (SR): expected adverse reaction (sign or symptom) observed \& reported under conditions (nature \& onset) prelisted (i.e., solicited) in CRF and considered as related to product administered. Solicited injection site reactions included pain, erythema, \& swelling. Reported AEs for each arm were presented as pre-specified in study protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.
| Participants | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Pain Post-any vaccination | 28 | 28 | 5 | 33 | 33 | 10 | 2 |
| Pain Post-vaccination 1 | 28 | 28 | 5 | 29 | 32 | 10 | 1 |
| Pain Post-vaccination 2 | — | — | — | 28 | 32 | 10 | 2 |
| Erythema Post-any vaccination | 2 | 0 | 0 | 4 | 5 | 0 | 0 |
| Erythema Post-vaccination 1 | 2 | 0 | 0 | 3 | 5 | 0 | 0 |
| Erythema Post-vaccination 2 | — | — | — | 2 | 4 | 0 | 0 |
| Swelling Post-any vaccination | 1 | 2 | 0 | 6 | 4 | 2 | 0 |
| Swelling Post-vaccination 1 | 1 | 2 | 0 | 3 | 3 | 2 | 0 |
| Swelling Post-vaccination 2 | — | — | — | 4 | 2 | 1 | 0 |
SR was an expected adverse reaction (sign or symptom) observed \& reported under conditions (nature \& onset) prelisted (i.e., solicited) in CRF \& considered as related to product administered. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia \& chills. Reported AEs for each arm were presented as pre-specified in study protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.
| Participants | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Fever Post-any vaccination | 5 | 8 | 1 | 9 | 16 | 10 | 0 |
| Fever Post-vaccination 1 | 5 | 8 | 1 | 6 | 11 | 10 | 0 |
| Fever Post-vaccination 2 | — | — | — | 7 | 12 | 8 | 0 |
| Headache Post-any vaccination | 17 | 17 | 6 | 26 | 31 | 10 | 5 |
| Headache Post-vaccination 1 | 17 | 17 | 6 | 22 | 27 | 9 | 3 |
| Headache Post-vaccination 2 | — | — | — | 21 | 27 | 7 | 3 |
| Malaise Post-any vaccination | 21 | 21 | 5 | 28 | 31 | 10 | 2 |
| Malaise Post-vaccination 1 | 21 | 21 | 5 | 25 | 28 | 9 | 2 |
| Malaise Post-vaccination 2 | — | — | — | 22 | 28 | 9 | 2 |
| Myalgia Post-any vaccination | 20 | 23 | 4 | 28 | 28 | 8 | 2 |
| Myalgia Post-vaccination 1 | 20 | 23 | 4 | 23 | 24 | 8 | 2 |
| Myalgia Post-vaccination 2 | — | — | — | 22 | 25 | 7 | 2 |
| Arthralgia Post-any vaccination | 7 | 13 | 2 | 20 | 23 | 10 | 2 |
| Arthralgia Post-vaccination 1 | 7 | 13 | 2 | 11 | 18 | 5 | 1 |
| Arthralgia Post-vaccination 2 | — | — | — | 17 | 19 | 7 | 2 |
| Chills Post-any vaccination | 14 | 17 | 4 | 20 | 29 | 9 | 1 |
| Chills Post-vaccination 1 | 14 | 17 | 4 | 15 | 23 | 8 | 0 |
| Chills Post-vaccination 2 | — | — | — | 17 | 25 | 7 | 1 |
An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product and which did not have any casual relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset window post-vaccination. Reported AEs for each arm were presented as pre-specified in the study protocol. In the data table, '0' in number analyzed field denotes that no participants were available for assessment for specified Group as no one in that group received vaccination 2.
| Participants | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Post Any vaccination | 17 | 4 | 8 | 10 | 15 | 5 | 3 |
| Post vaccination 1 | 17 | 4 | 8 | 10 | 10 | 5 | 2 |
| Post vaccination 2 | — | — | — | 5 | 10 | 2 | 1 |
SAEs: any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs: event for which ongoing monitoring \& rapid communication by investigator to the sponsor was done. MAAE was a new onset or worsening of a condition that prompted participant or participant's parent/legally acceptable representative to seek unplanned medical advice at physician's office or emergency department. Reported AEs for each arm were presented as pre-specified in study protocol.
| Participants | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| SAEs | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| AESI | 3 | 3 | 2 | 3 | 1 | 1 | 1 |
| MAAEs | 6 | 2 | 1 | 6 | 6 | 3 | 2 |
Laboratory tests: hemoglobin (male \& female), above \& below normal white blood cell, lymphocytes, neutrophils \& eosinophils, platelet count, creatinine \& blood urea nitrogen, hyponatremia \& hypernatremia, hyperkalemia \& hypokalemia, hyperglycemia (non-fasting), hypoproteinemia, alkaline phosphate, alanine aminotransferase, aspartate aminotransferase, bilirubin (with any increase in liver function test \[LFT\], bilirubin (normal LFT), prothrombin \& partial thromboplastin time (seconds), Urine: protein, glucose \& blood. US FDA "Toxicity Grading Scale for Healthy Adults \& Adolescent Volunteers" was used for grading; Grade 1=mild, Grade 2=moderate \& Grade 3=severe. In the data table, 'number analyzed'=participants with available data for each specified category \& '0'=none of participants were available for assessment for specified Group.
| Participants | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Hemoglobin (Female): Grade 1 | 0 | 1 | 1 | 2 | 0 | 0 | 1 |
| Hemoglobin (Female): Grade 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hemoglobin (Female): Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin (Male): Grade 1 | 1 | 2 | 0 | 0 | 1 | 1 | 0 |
| Hemoglobin (Male): Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin (Male): Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Above normal white blood cell: Grade 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Above normal white blood cell: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Above normal white blood cell: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Below normal white blood cell: Grade 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 |
| Below normal white blood cell: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Below normal white blood cell: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets Decreased: Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets Decreased: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets Decreased: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Absolute Neutrophils Decreased: Grade 1 | 1 | 1 | 1 | 0 | 6 | 0 | 0 |
| Absolute Neutrophils Decreased: Grade 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Absolute Neutrophils Decreased: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Absolute Lymphocytes Decreased: Grade 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Absolute Lymphocytes Decreased: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Absolute Lymphocytes Decreased: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Absolute Eosinophils: Grade 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Absolute Eosinophils: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Absolute Eosinophils: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia: Grade 1 | 1 | 1 | 3 | 0 | 1 | 0 | 0 |
| Hyponatremia: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia: Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia: Grade 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypernatremia: Grade 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia: Grade 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Hyperkalemia: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia: Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia: Grade 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Hypokalemia: Grade 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Blood Urea Nitrogen: Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Urea Nitrogen: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Urea Nitrogen: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine: Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia: Grade 1 | 2 | 0 | 0 | 2 | 3 | 0 | 0 |
| Hyperglycemia: Grade 2 | 2 | 0 | 0 | 1 | 2 | 0 | 0 |
| Hyperglycemia: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoproteinemia: Grade 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Hypoproteinemia: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoproteinemia: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase: Grade 1 | 1 | 0 | 2 | 0 | 1 | 2 | 0 |
| Alanine aminotransferase: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase: Grade 1 | 1 | 0 | 2 | 0 | 1 | 0 | 0 |
| Aspartate aminotransferase: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphate: Grade 1 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Alkaline phosphate: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphate: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin - with any increase in LFT: Grade 1 | 0 | — | 0 | — | 0 | 0 | — |
| Bilirubin - with any increase in LFT: Grade 2 | 0 | — | 0 | — | 0 | 0 | — |
| Bilirubin - with any increase in LFT: Grade 3 | 0 | — | 0 | — | 0 | 0 | — |
| Bilirubin - with normal in LFT: Grade 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Bilirubin - with normal in LFT: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin - with normal in LFT: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prothrombin time: Grade 1 | 0 | 2 | 0 | 3 | 3 | 0 | 0 |
| Prothrombin time: Grade 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Prothrombin time: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Partial thromboplastin time: Grade 1 | 1 | 2 | 1 | 3 | 2 | 0 | 0 |
| Partial thromboplastin time: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Partial thromboplastin time: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urine - glucose: Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urine - glucose: Grade 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Urine - glucose: Grade 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urine - protein: Grade 1 | 3 | 5 | 2 | 1 | 4 | 1 | 1 |
| Urine - protein: Grade 2 | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
| Urine - protein: Grade 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Urine - blood: Grade 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Urine - blood: Grade 2 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Urine - blood: Grade 3 | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution. Data for this OM was planned to be collected and analyzed for combined population (FEC+ Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
| titer | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 1 | 5.00 (NA to NA) | 5.00 (NA to NA) | 5.00 (NA to NA) | 5.00 (NA to NA) | 5.00 (NA to NA) | 5.00 (NA to NA) | 5.00 (NA to NA) |
GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.
| titer | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 22 | 24.0 (15.3 to 37.6) | 29.7 (14.8 to 59.6) | 6.66 (3.61 to 12.3) | 35.2 (21.0 to 59.0) | 27.7 (16.4 to 46.9) | 68.2 (29.0 to 160) | 12.8 (2.52 to 65.1) |
GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.
| titer | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: Group 2: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 36 | 13.6 (8.88 to 20.9) | 30.1 (15.5 to 58.6) | 6.48 (3.68 to 11.4) | 174 (111 to 273) | 223 (147 to 336) | 416 (303 to 570) | 11.6 (2.43 to 55.5) |
SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 1.
| ratio | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22 | 4.80 (3.07 to 7.52) | 5.93 (2.95 to 11.9) | 1.36 (0.704 to 2.62) | 7.05 (4.21 to 11.8) | 5.55 (3.28 to 9.37) | 13.6 (5.79 to 32.1) | 1.32 (0.682 to 2.57) |
SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (Day 36) and pre-vaccination (on Day 1) i.e., Day 36/Day 1.
| ratio | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36 | 2.84 (1.83 to 4.40) | 6.03 (3.10 to 11.7) | 1.32 (0.714 to 2.46) | 34.9 (22.3 to 54.6) | 44.6 (29.5 to 67.3) | 83.1 (60.7 to 114) | 1.20 (0.777 to 1.86) |
SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 1.
| percentage of participants | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| >=2-fold rise | 77.4 (58.9 to 90.4) | 66.7 (44.7 to 84.4) | 6.7 (0.2 to 31.9) | 81.3 (63.6 to 92.8) | 74.2 (55.4 to 88.1) | 100 (69.2 to 100) | 12.5 (0.3 to 52.7) |
| >=4-fold rise | 58.1 (39.1 to 75.5) | 58.3 (36.6 to 77.9) | 6.7 (0.2 to 31.9) | 71.9 (53.3 to 86.3) | 54.8 (36.0 to 72.7) | 100 (69.2 to 100) | 12.5 (0.3 to 52.7) |
SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (on Day 36) and pre-vaccination (on Day 1) i.e., Day 36/Day 1.
| percentage of participants | Cohort 1: Group 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: Group 2: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Group 3: Placebo | Cohort 2: Group 4: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: Group 5: SARS-CoV-2 Vaccine Low Dose | Cohort 2: Group 6: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Group 7: Placebo |
|---|---|---|---|---|---|---|---|
| >=2-fold rise | 58.3 (36.6 to 77.9) | 77.8 (52.4 to 93.6) | 8.3 (0.2 to 38.5) | 96.6 (82.2 to 99.9) | 100 (88.8 to 100) | 100 (69.2 to 100) | 12.5 (0.3 to 52.7) |
| >=4-fold rise | 45.8 (25.6 to 67.2) | 66.7 (41.0 to 86.7) | 8.3 (0.2 to 38.5) | 96.6 (82.2 to 99.9) | 100 (88.8 to 100) | 100 (69.2 to 100) | 12.5 (0.3 to 52.7) |
Seroconversion was defined as participants with a Baseline (Day 1) titer values below lower limit of quantification (LLOQ) with a detectable neutralization antibody titer above assay LLOQ post injection (at Day 22). LLOQ of the neutralization assay was a titer of 10.
| percentage of participants | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22 | 77.4 (58.9 to 90.4) | 66.7 (44.7 to 84.4) | 6.7 (0.2 to 31.9) | 81.3 (63.6 to 92.8) | 74.2 (55.4 to 88.1) | 100 (69.2 to 100) | 12.5 (0.3 to 52.7) |
Seroconversion was defined as participants with a Baseline (Day 1) titer values below LLOQ with a detectable neutralization antibody titer above assay LLOQ post injection (at Day 36). LLOQ of the neutralization assay was a titer of 10.
| percentage of participants | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36 | 58.3 (36.6 to 77.9) | 77.8 (52.4 to 93.6) | 8.3 (0.2 to 38.5) | 96.6 (82.2 to 99.9) | 100 (88.8 to 100) | 100 (69.2 to 100) | 12.5 (0.3 to 52.7) |
GMC of Anti-S binding antibodies were assessed using enzyme-linked immunosorbent assay (ELISA) and were measured in ELISA unit/mL (ELU/mL). Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
| ELU/mL | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Day 1 | 10.8 (9.08 to 12.7) | 10.8 (8.84 to 13.1) | 9.45 (NA to NA) | 10.1 (8.78 to 11.7) | 10.5 (8.93 to 12.3) | 10.3 (8.52 to 12.4) | 14.4 (7.08 to 29.4) |
| Day 22 | 239 (153 to 375) | 372 (192 to 723) | 13.2 (7.84 to 22.4) | 448 (249 to 805) | 476 (279 to 812) | 1618 (984 to 2660) | 34.5 (5.22 to 228) |
| Day 36 | 188 (110 to 319) | 310 (165 to 582) | 14.1 (7.52 to 26.3) | 3618 (2431 to 5382) | 4903 (3326 to 7228) | 10952 (7252 to 16540) | 34.4 (5.31 to 223) |
| Day 91 | 185 (36.4 to 936) | 1122 (117 to 10789) | 31.2 (NA to NA) | — | — | — | — |
| Day 112 | — | — | — | 4548 (1090 to 18981) | 1435 (696 to 2962) | 2782 (1138 to 6799) | 96.3 (6.61 to 1402) |
| Day 181 | 62.8 | 23251 | — | — | — | — | — |
| Day 202 | — | — | — | 384 | 1209 (344 to 4257) | — | 17316 |
Binding antibody titers were evaluated by ELISA. Fold-rise was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 22/Day 1, Day 36/Day 1, Day 91/Day 1, Day 112/Day 1, Day 181/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
| ratio | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Day 22/Day 1 | 22.5 (13.9 to 36.2) | 36.7 (17.5 to 76.9) | 1.28 (0.757 to 2.15) | 44.2 (24.4 to 80.0) | 45.3 (26.6 to 77.3) | 158 (93.7 to 265) | 2.39 (0.626 to 9.13) |
| Day 36/Day 1 | 19.5 (11.1 to 34.1) | 30.2 (14.6 to 62.7) | 1.34 (0.706 to 2.53) | 354 (228 to 551) | 466 (318 to 682) | 1067 (712 to 1601) | 2.38 (0.645 to 8.81) |
| Day 91/Day 1 | 26.8 (4.80 to 150) | 135 (9.27 to 1971) | 2.83 (NA to NA) | — | — | — | — |
| Day 112/Day 1 | — | — | — | 481 (115 to 2009) | 131 (61.0 to 282) | 271 (110 to 670) | 5.40 (0.445 to 65.5) |
| Day 181/Day 1 | 6.65 | 2460 | — | — | — | — | — |
| Day 202/Day 1 | — | — | — | 40.6 | 101 (25.9 to 392) | — | 125 |
Binding antibody titers were evaluated by ELISA. Fold-rise (2-fold and 4-fold) was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 22/Day 1, Day 36/Day 1, Day 91/Day 1, Day 112/Day 1, Day 181/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
| percentage of participants | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Day 22/Day 1: >=2-fold rise | 100 (88.8 to 100) | 100 (84.6 to 100) | 6.7 (0.2 to 31.9) | 93.8 (79.2 to 99.2) | 96.9 (83.8 to 99.9) | 100 (69.2 to 100) | 22.2 (2.8 to 60.0) |
| Day 22/Day 1: >=4-fold rise | 90.3 (74.2 to 98.0) | 86.4 (65.1 to 97.1) | 6.7 (0.2 to 31.9) | 90.6 (75.0 to 98.0) | 93.8 (79.2 to 99.2) | 100 (69.2 to 100) | 22.2 (2.8 to 60.0) |
| Day 36/Day 1: >=2-fold rise | 95.8 (78.9 to 99.9) | 100 (81.5 to 100) | 8.3 (0.2 to 38.5) | 100 (88.1 to 100) | 100 (88.8 to 100) | 100 (69.2 to 100) | 22.2 (2.8 to 60.0) |
| Day 36/Day 1: >=4-fold rise | 87.5 (67.6 to 97.3) | 88.9 (65.3 to 98.6) | 8.3 (0.2 to 38.5) | 100 (88.1 to 100) | 100 (88.8 to 100) | 100 (69.2 to 100) | 22.2 (2.8 to 60.0) |
| Day 91/Day 1: >=2-fold rise | 85.7 (42.1 to 99.6) | 100 (59.0 to 100) | 25.0 (0.6 to 80.6) | — | — | — | — |
| Day 91/Day 1: >=4-fold rise | 85.7 (42.1 to 99.6) | 100 (59.0 to 100) | 25.0 (0.6 to 80.6) | — | — | — | — |
| Day 112/Day 1: >=2-fold rise | — | — | — | 100 (78.2 to 100) | 100 (85.2 to 100) | 100 (69.2 to 100) | 50.0 (11.8 to 88.2) |
| Day 112/Day 1: >=4-fold rise | — | — | — | 100 (78.2 to 100) | 100 (85.2 to 100) | 100 (69.2 to 100) | 50.0 (11.8 to 88.2) |
| Day 181/Day 1: >=2-fold rise | 100 (2.5 to 100) | 100 (2.5 to 100) | — | — | — | — | — |
| Day 181/Day 1: >=4-fold rise | 100 (2.5 to 100) | 100 (2.5 to 100) | — | — | — | — | — |
| Day 202/Day 1: >=2-fold rise | — | — | — | 100 (2.5 to 100) | 100 (76.8 to 100) | — | 100 (2.5 to 100) |
| Day 202/Day 1: >=4-fold rise | — | — | — | 100 (2.5 to 100) | 100 (76.8 to 100) | — | 100 (2.5 to 100) |
GMTs of SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Titers were expressed in terms of 1/dilution. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
| titers | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Day 91 | 13.7 (6.70 to 28.1) | 113 (10.2 to 1263) | 9.33 (NA to NA) | — | — | — | — |
| Day 112 | — | — | — | 322 (56.3 to 1842) | 69.5 (31.4 to 154) | 177 (52.7 to 593) | 23.1 (2.91 to 183) |
| Day 181 | 21.0 | 2993 | — | — | — | — | — |
| Day 202 | — | — | — | 45.0 | 120 (25.5 to 568) | — | 3490 |
SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., for Cohort 1: Day 91/Day 1, Day 181/Day 1; Cohort 2: Day 112/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
| ratio | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Day 91/Day 1 | 3.17 (1.49 to 6.74) | 22.7 (2.03 to 253) | 2.18 (NA to NA) | — | — | — | — |
| Day 112/Day 1 | — | — | — | 64.4 (11.3 to 368) | 13.9 (6.28 to 30.7) | 35.3 (10.5 to 119) | 2.76 (NA to NA) |
| Day 181/Day 1 | 4.20 | 599 | — | — | — | — | — |
| Day 202/Day 1 | — | — | — | 9.00 | 24.1 (5.09 to 114) | — | — |
SARS-CoV-2 neutralizing antibodies (D614G variant) was measured using a neutralization assay. Fold-rise (2-fold and 4-fold) was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 91/Day 1, Day 112/Day 1, Day 181/Day 1, and Day 202/Day 1. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
| percentage of participants | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Group 3: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Day 91/Day 1: >=2-fold rise | 71.4 (29.0 to 96.3) | 71.4 (29.0 to 96.3) | 25.0 (0.6 to 80.6) | — | — | — | — |
| Day 91/Day 1: >=4-fold rise | 57.1 (18.4 to 90.1) | 71.4 (29.0 to 96.3) | 25.0 (0.6 to 80.6) | — | — | — | — |
| Day 112/Day 1: >=2-fold rise | — | — | — | 93.3 (68.1 to 99.8) | 90.9 (70.8 to 98.9) | 100 (69.2 to 100) | 40.0 (5.3 to 85.3) |
| Day 112/Day 1: >=4-fold rise | — | — | — | 86.7 (59.5 to 98.3) | 77.3 (54.6 to 92.2) | 100 (69.2 to 100) | 20.0 (0.5 to 71.6) |
| Day 181/Day 1: >=2-fold rise | 100 (2.5 to 100) | 100 (2.5 to 100) | — | — | — | — | — |
| Day 181/Day 1: >=4-fold rise | 100 (2.5 to 100) | 100 (2.5 to 100) | — | — | — | — | — |
| Day 202/Day 1: >=2-fold rise | — | — | — | 100 (2.5 to 100) | 91.7 (61.5 to 99.8) | — | — |
| Day 202/Day 1: >=4-fold rise | — | — | — | 100 (2.5 to 100) | 83.3 (51.6 to 97.9) | — | — |
Seroconversion was defined as participants with a Baseline (Day 1) titer values below lower limit of quantification (LLOQ) with a detectable neutralization antibody titer above assay LLOQ post injection. LLOQ of the neutralization assay was a titer of 10. Data for this OM was planned to be collected and analyzed for combined population (FEC + Sentinel Cohort) in which same dose-level groups in Sentinel Cohort and FEC were pooled for analysis.
| percentage of participants | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Day 91 | 71.4 (29.0 to 96.3) | 71.4 (29.0 to 96.3) | 25.0 (0.6 to 80.6) | — | — | — | — |
| Day 112 | — | — | — | 93.3 (68.1 to 99.8) | 90.9 (70.8 to 98.9) | 100 (69.2 to 100) | 40.0 (5.3 to 85.3) |
| Day 181 | 100 (2.5 to 100) | 100 (2.5 to 100) | — | — | — | — | — |
| Day 202 | — | — | — | 100 (2.5 to 100) | 91.7 (61.5 to 99.8) | — | — |
Virologically-confirmed COVID-19-like illness was defined by specified clinical symptoms and signs and confirmed by positive result for SARS-CoV-2 by nucleic acid amplification test (NAAT) on a respiratory sample in association with a COVID-19-like illness.
No measurements were reported for this outcome.
Serologically-confirmed SARS-CoV-2 infection as defined by SARS-CoV-2 Nucleoprotein specific antibody detection immunoassay was reported in this outcome measure.
No measurements were reported for this outcome.
Correlate of risk / protection based on antibody responses to SARS-CoV-2 was evaluated using virus neutralization or ELISA, considering virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection.
No measurements were reported for this outcome.
Collected over Unsolicited AEs were collected within 21 days post-vaccination. Solicited reaction data were collected within 7 days post any vaccination. SAE data were collected from Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 groups and up to Day 387 for Cohort 2 groups). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | 0/37 (0%) | 0/37 (0%) | 31/37 (83.8%) |
| Cohort 1: SARS-CoV-2 Vaccine Low Dose | 0/34 (0%) | 0/34 (0%) | 30/34 (88.2%) |
| Cohort 1: Placebo | 0/18 (0%) | 1/18 (5.6%) | 11/18 (61.1%) |
| Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | 0/36 (0%) | 0/36 (0%) | 34/36 (94.4%) |
| Cohort 2: SARS-CoV-2 Vaccine Low Dose | 0/36 (0%) | 0/36 (0%) | 35/36 (97.2%) |
| Cohort 2: SARS-CoV-2 Vaccine Medium Dose | 0/10 (0%) | 1/10 (10%) | 10/10 (100%) |
| Cohort 2: Placebo | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Event | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Cystitis HaemorrhagicRenal and urinary disorders | 0/37 | 0/34 | 0/18 | 0/36 | 0/36 | 1/10 | 0/9 |
| Covid-19Infections and infestations | 0/37 | 0/34 | 1/18 | 0/36 | 0/36 | 0/10 | 0/9 |
| Event | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo |
|---|---|---|---|---|---|---|---|
| Injection Site PainGeneral disorders | 28/37 | 28/34 | 5/18 | 33/36 | 33/36 | 10/10 | 2/9 |
| MalaiseGeneral disorders | 21/37 | 21/34 | 5/18 | 28/36 | 31/36 | 10/10 | 2/9 |
| PyrexiaGeneral disorders | 5/37 | 8/34 | 1/18 | 10/36 | 16/36 | 10/10 | 0/9 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/37 | 13/34 | 2/18 | 20/36 | 23/36 | 10/10 | 2/9 |
| HeadacheNervous system disorders | 18/37 | 18/34 | 7/18 | 26/36 | 31/36 | 10/10 | 5/9 |
| ChillsGeneral disorders | 14/37 | 17/34 | 4/18 | 20/36 | 29/36 | 9/10 | 1/9 |
| MyalgiaMusculoskeletal and connective tissue disorders | 20/37 | 23/34 | 4/18 | 28/36 | 28/36 | 8/10 | 2/9 |
| DiarrhoeaGastrointestinal disorders | 1/37 | 2/34 | 0/18 | 0/36 | 1/36 | 2/10 | 1/9 |
| Injection Site SwellingGeneral disorders | 1/37 | 2/34 | 0/18 | 6/36 | 4/36 | 2/10 | 0/9 |
| Injection Site ErythemaGeneral disorders | 2/37 | 0/34 | 0/18 | 4/36 | 5/36 | 0/10 | 0/9 |
Analysis was performed on all enrolled participants according to the intervention to which they were randomized. Data for baseline characteristics was planned to be collected and analyzed for combined population (Full Enrollment Cohort + Sentinel Cohort) in which the same dose-level groups in Sentinel Cohort and Full Enrollment Cohort were pooled for the analysis. Since Sentinel Cohort: SARS-CoV-2 Vaccine Medium Dose group received 2 injections; they were presented under Cohort 2 for analysis.
| Age, Continuous(years) | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 44.15 ± 16.19 | 41.96 ± 17.05 | 39.77 ± 14.96 | 36.21 ± 13.00 | 34.96 ± 13.22 | 31.00 ± 8.94 | 38.79 ± 16.24 | 38.01 ± 14.68 |
| Sex: Female, Male(Participants) | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 10 | 10 | 5 | 18 | 25 | 3 | 6 | 77 |
| Male | 17 | 16 | 8 | 20 | 29 | 7 | 8 | 105 |
| Race (NIH/OMB)(Participants) | Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 1: SARS-CoV-2 Vaccine Low Dose | Cohort 1: Placebo | Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose | Cohort 2: SARS-CoV-2 Vaccine Low Dose | Cohort 2: SARS-CoV-2 Vaccine Medium Dose | Cohort 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 5 | 5 | 3 | 12 | 7 | 10 | 3 | 45 |
| Asian | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 3 |
| Black or African American | 0 | 2 | 0 | 2 | 8 | 0 | 4 | 16 |
| White | 22 | 18 | 10 | 24 | 34 | 0 | 5 | 113 |
| More than one race | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Mar 2021 to primary completion in Jun 2022, 15 months.
Results were first posted in Dec 2023, 1 year 5 months after primary completion. A results delay was requested in Jun 2023.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →